
INKT
MiNK Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About INKT
Mink Therapeutics, Inc.
A biotechnology company focused on developing cancer immunotherapies and autoimmune disease treatments
Biological Technology
Invalid Date
10/15/2021
NASDAQ Stock Exchange
23
12-31
Common stock
149 Fifth Avenue, Suite 500, New York, NY 10010
--
MiNK Therapeutics, Inc., was incorporated in Delaware in July 2017. The Company is a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf iNKT cell therapies for the treatment of cancer and other immune-mediated diseases. The company is leveraging its platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of natural and engineered iNKT cells with multiple clinical and preclinical readouts expected in 2021 and 2022. The company's strategy is to advance an accessible, scalable and effective cell therapy platform that leverages the innate and durable biological advantages of iNKT cells to optimize scalability and rapid clinical development.
Company Financials
EPS
INKT has released its 2024 Q4 earnings. EPS was reported at -0.62, versus the expected -0.50, missing expectations. The chart below visualizes how INKT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available